RJA
AXDX icon

Raymond James & Associates’s Accelerate Diagnostics AXDX Stock Holding History

Raymond James & Associates’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,700
Closed -$13.8K – 3802
2023
Q2 		$13.8K Sell
1,700
-50
-3% -$375 ﹤0.01% 3795
2023
Q1 		$12.2K Hold
1,750
– – ﹤0.01% 3831
2022
Q4 		$12.4K Hold
1,750
– – ﹤0.01% 3837
2022
Q3 		$27K Buy
+1,750
New +$29K ﹤0.01% 3768
2018
Q3 		– Sell
-1,056
Closed -$235K – 3643
2018
Q2 		$235K Sell
1,056
-2,808
-73% -$628K ﹤0.01% 3164
2018
Q1 		$883K Buy
3,864
+35
+0.9% +$9.19K ﹤0.01% 2219
2017
Q4 		$1M Buy
3,829
+1,625
+74% +$381K ﹤0.01% 2127
2017
Q3 		$495K Buy
2,204
+478
+28% +$117K ﹤0.01% 2497
2017
Q2 		$472K Buy
1,726
+198
+13% +$53.7K ﹤0.01% 2454
2017
Q1 		$370K Buy
1,528
+334
+28% +$76.3K ﹤0.01% 2562
2016
Q4 		$248K Buy
+1,194
New +$284K ﹤0.01% 2759

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
CI
Chartist Inc Seal Beach, California $160M AUM 15.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James & Associates's AXDX Position: Q3 2023 in Review

Raymond James & Associates sold out of Accelerate Diagnostics (AXDX) in Q3 2023, closing a stake of 1,700 shares — an estimated $13.8K sold.

Raymond James & Associates first reported a position in AXDX in Q4 2016 and held it in 11 quarters. The position peaked at $1M in Q4 2017. 38 funds tracked by Wall St. Rank hold AXDX as of Q3 2023.

  • Raymond James & Associates reported no remaining Accelerate Diagnostics position as of Q3 2023 after selling out during the quarter.
  • Raymond James & Associates sold 1,700 Accelerate Diagnostics shares in Q3 2023, an estimated $13.8K.
  • Raymond James & Associates first reported a position in Accelerate Diagnostics in Q4 2016 and held it in 11 quarters.
  • Raymond James & Associates's Accelerate Diagnostics position peaked at $1M in Q4 2017.
  • 38 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2023.

Based on Raymond James & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.